[Broncaspin in the therapy of pediatric diseases of the respiratory tract]

A paediatric suspension of Broncaspin was administered to 32 children aged 2-12 yr hospitalised for acute respiratory infection of the respiratory apparatus or hyperpirexia with no evident location. The drug was given as the sole treatment in 9 cases, whereas combination with antibacterial drugs proved indispensable in the other 23 cases. The satisfactory results obtained, together with its excellent tolerability, show that the new preparation is active, and is capable of rapidly eliminating the symptoms, so that the general clinical picture is both evidently and persistently improved.

[Clinical evaluation of the activity of 2 preparations with similar action in bronchopneumopathies in the aged]

The results obtained in a single blind controlled study using a new preparation, guacetisal, and an already available similar product based on dimethylaminophenazone guaiacolglycolate and calcium ethylcamphorate, are reported. The drugs were administered to 28 elderly patients of both sexes suffering from bronchopneumopathies for a period of 7 consecutive days with 2 suppositories/day. The results generally favoured the new product. Tolerance was very good at all levels.

[Guacetisal: a new molecule with balsamic-antiphlogistic action. Clinical study]

An open clinical trial was run on the therapeutic efficacy of a new balsamic-antiinflammatory molecule, guacetisal (presented as 500 mg Broncaspin capsules). The drug was given for a minimum of 7 days to 45 male and female patients with an average age of 64 yr suffering from variously serious diseases of the airways. The concomitant administration of fluidifying, balsamic, steroid, antipyretic and anti-inflammatory drugs was avoided, whereas various combinations of cardiokinetics, diuretics, theophyllines, and antibiotics were used where required. Clinical assessment of the parameters chosen pointed to the good therapeutic activity of the preparation, which is specifically indicated in inflammatory conditions of the airways, especially chronic forms subject to periodic recrudescence. Its equally good tolerability serves to make guacetisal extremely easy to use, with the results that its employment in non-specialist environments can also be recommended.

[Clinical evaluation of the therapeutic effectiveness of a new drug with anti-inflammatory-balsamic action, guacetisal, in respiratory tract diseases]

In 40 patients with bronchopulmonary diseases, in prevalence of chronic type, the therapeutic value of a new antiphlogistic-balsamic compound was evaluated. The favourable results obtained, particularly as far as the rapidity of regression of signs and symptoms is concerned, showed that this drug may have a significant role in a combined scheme of treatment.

[Effects of guaiacolic ester of acetylsalicylic acid on spirometric and plethysmographic parameters in subjects with chronic obstructive bronchopneumopathy]

The effects of oral administration of guaiacolic ester of acetyl salicilic acid in 24 patients with chronic obstructive lung disease have been evaluated. 1.5 g of this drug were given daily into 3 administrations improving both objective and subjective symptomatology in 19 of the 24 patients after 1 or 3 weeks of treatment. Moreover, a statistically significant improvement of FEV 1" (p less than 0.001), Raw (p less than 0.005) and FEV 1"/VC (p less than 0.01) was observed. The remaining 5 patients discontinued the treatment failing the improvement of the subjective symptomatology.

[Preliminary study of guacetisal in chronic bronchitis]

A single-blind, between-patients trial was run on two randomly formed groups of 15 hospitalised male patients with chronic obstructive bronchitis, carefully selected to rule out excessive interference on the part of other pathologies or lund complications, in which 3 tablespoonfuls a day Broncaspin suspension were compared with the same dose of a recognised commercial preparation composed by sodium thymosulphonate, ammonium acetate, codeine, and tincture of datura. The clinical and instrumental data showed that Broncaspin had greater therapeutic activity. The local and general tolerability of the two preparations was uneceptionable.

[Clinical trials of a new preparation in chronic bronchopneumopathies]

The new preparation Broncaspin (guacetisal) has been experimented in the form of 1.2 g suppositories and 5% suspension, in 40 patients suffering from chronic bronchopneumopathy at acute phase. The drug exerted a marked therapeutic action in objective and subjective symptomatology in 87.5% of cases. The action was manifold in relation to the typical expectorant fluidifying, bronchiole disobstructing and anti-inflammatory characteristics of the drug. Tolerance was always excellent.

[Guacetisal in the treatment of acute and chronic bronchopneumopathy]

30 patients of senile age suffering from acute and chronic bronchopneumopathies, the latter in acute phase, have been treated with guacetisal, a new pharmacological substance with anti-inflammatory, fluidifying and bechic properties. The therapeutic results, obtained with 1.2 g suppositories, were definitely positive in a high percentage of case (83.3%).

[The use of guacetisal in chronic obstructive bronchopneumopathy. Controlled clinical study]

A single-blind, between-patients trial was run to compare the fluidifying, expectorant, antitussive, antipyretic and anti-inflammatory activity, and the local and systemic tolerance of guacetisal, an active principle obtained by the esterification of acetylsalicylic acid and guaiacol, and oxolamine phosphate, in which the suspension formulation for adults was administered to 30 presenile and senile patients of both sexes with chronic obstructive bronchopathy. A higher activity on the part of guacetisal was noted. The results obtained are illustrated and discussed.

[Evaluation of the therapeutic effects of broncaspin in chronic bronchopneumopathies]

A controlled single-blind clinical trial was made with Broncaspin, on original synthetic molecule obtained by condensing acetylsalicylic acid and guaiacol, in a comparison of its local and general tolerance, and antipyretic, antiexudative and balsamic properties with those of dimethylaminophenazone guaiacolglycolate, a well-known preparation, in two randomly composed groups of 15 patients with chronic obstructive bronchial and lung diseases, using 1,2 g Broncaspin suppositories and the commercial form of the other product twice a day for 14 consecutive days. Therapeutic assessment was based on the symptomatological, spirometric and blood gas data.

[Treatment of bronchial inflammatory disorders with guacetisal]

A comparative trial conducted on 48 male and 9 female patients suitably selected in terms of indication consisted of a first stage in which a completely random, doubleblind comparison was made between acetylsalicylic acid, guacetisal and guaiacol carbonate (preparations A, B, and C) while in the second stage an association of bromexine, acetylsalicylic acid and codeine phosphate (preparation D) was examined in terms of activity and tolerance in an open trial. Statistical analysis showed the superiority of preparation B with respect to most of the parameters taken into consideration.

[Clinico-functional observations on the use of guacetisal in the treatment of chronic obstructive bronchopneumopathy]

The results of an approximately 14-day treatment with 500 mg broncaspin capsules in 25 patients with recrudescent chronic bronchitis are presented. There was a marked, constant improvement in the subjective and objective symptomatology, and in respiratory function indices. The expectoration cell parameters displayed changes consonant with the therapeutic effect. Local and general tolerance were good overall.

[Controlled clinical study of the treatment of chronic bronchitis with guacetisal]

Controlled clinical research has been carried out on the activity and tolerance of a new active principle, guacetisal (Broncaspin) obtained from the esterification of acetylsalicylic acid with guaiacol, in the treatment of chronic bronchitis. The drug's therapeutic response was evaluated with respect to that of bromexine. Guacetisal was generally well tolerated. It had no unwanted side-effects on the main haematochemical parameters or on the function of organs and systems. It was found to have considerable therapeutic effectiveness, at times even superior to that of the control drug, with respect to general symptomatology and at respiratory system level. It produced early, lasting reduction in temperature, heart frequency, dyspnoea, duration of expirium and in the intensity and number of coughing attacks. It also led to an appreciable improvement in thoracic objectivity and the X-ray picture. Variations in respiratory functional parameters were of considerable interest and from these it is concluded that guacetisal exerts its polyvalent activity to a proportionately higher extent in the bronchial districts more seriously involved in the inflammatory process, inducing an elective improvement in bronchial permeability, a reduction in total pulmonary resistances--with consequent tendency for ventilation-perfusion relations to normalise--as well as an improvement in gas exchanges and patient oxygenation.

[The use of a new balsamic expectorant in bronchopulmonary pathology in children]

The therapeutic effectiveness of a new antiinflammatory-expectorant drug, guacetisal (Broncaspin) has been compared with that of a well known mucolytic, bromexine, already available for therapy, in the paediatric suspension formula. The study was carried out on 26 children in the 1st Paediatrics clinic of Milan University. The children were suffering from inflammation of the respiratory apparatus. It is concluded that the new drug possesses greated clinical effectiveness.

[Clinical considerations on a new synthetic compound with antipyretic and anticatarrhal action]

A Broncaspin suspension was administered for an average of 6-7 days (1/2 teaspoonful twice a day to patients up to 3 yr old; 1 teaspoonful twice a day to those over 3) in the treatment of acute febrile diseases of the upper airways in 16 male and 14 female children aged 5 months to 5 and 3/12 yr. Satisfactory results were obtained in all cases.

[Broncaspin in respiratory diseases in pediatrics. Clinical contribution]

Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect. The preparation was outstanding for speed of action, local and general tolerance, and the absence of haematological, hepatic or renal side-effects. The new drug is considered to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.

[Clinical study of a preparation with bronchomucotropic activity: guacetisal]

An open clinical study has been carried out on 40 patients of both sexes suffering from prevalently chronic bronchopneumopathy, with a suspension of guacetisal for adults. The drug is a new bronchomucotropic synthesized by the Bayer Italia S.p.A. Research Laboratories. The improvement in the clinical picture was very evident in 55% of cases and is in favour of an overall positive opinion of the drug's activity bearing in mind that the pathology considered would not in any case have permitted the achievement of complete resolution. The drug was very well tolerated and presented marked mucopoietic and anti-inflammatory properties at a dose of 1 spoonful (10 ml) 2-3 times a day.

[Clinico-functional data concerning chronic asthmatic bronchitis patients treated wih guacetisal]

Guacetisal was administered to a group of patients suffering from chronic asthmatic bronchitis. The drug in question was shown to possess a good fluidifying, expectorant and indirect anti-cough action, by means of an initial increase of the bronchial secretions and a subsequent progressive decrease of secretions towards the end of the treatment. The analysis of the respiratory parameters examined showed no modifications of statistical significance.

[Lysine acetylsalicylate in the treatment of postoperative pain in obstetric and gynecological surgery]

The analgesic activity of acetylsalicylate of lysine (ASL) was evaluated in postoperative pain. Acetylsalicylate of lysine was administered i.v. to 345 patients submitted to obstetrical and gynaecological surgery. Excellent results were obtained in 77.4% of the cases and no severe side-effects were observed.

Impaired insulin secretion in human diabetes mellitus. II. A possible role for prostaglandins

Human diabetes mellitus is characterized by impaired insulin response to intravenous glucose. In search of possible endogenous factors which impair insulin release, we have investigated the effect of lysine acetylsalicylate (LAS), an inhibitor of endogenous prostaglandin (PGs) synthesis, upon insulin responses to glucose and arginine in subjects with type II (adult-on-set) diabetes mellitus. Acute insulin response to glucose (20 g) was significantly increased by LAS (response before LAS=26 +/- 10%; during LAS=77+15%, mean+/-SEM, mean change 3-10 min insulin, % basal, n=8, p 0.01), as well as second phase insulin secretion (before LAS=1437+/-316%; during LAS=3960+/-550%, change 10-60 min, uU/ml-min, % basal, p less than 0.01). This effect was associated with an increase in glucose disappearance rates (p less than 0.01). Acute insulin response to arginine (5 g iv) was also increased by LAS infusion. These results suggest that endogenous PGs may be one of the factors which impair insulin secretion in human diabetes.